James Rae, PhD
Thomas H Simpson Collegiate Professor of Cancer Research
Associate Professor of Internal Medicine
Associate Professor of Pharmacology
[email protected]

Available to mentor
James Rae, PhD
Associate Professor
  • Center Memberships
  • Recent Publications
    • Center Memberships
    • Center Member
      Rogel Cancer Center
    Recent Publications See All Publications
    • Journal Article
      Discovery of ERD-12310A as an Exceptionally Potent and Orally Efficacious PROTAC Degrader of Estrogen Receptor α (ERα).
      Rej RK, Hu B, Chen Z, Acharyya RK, Wu D, Metwally H, McEachern D, Wang Y, Jiang W, Bai L, Nishimura LS, Gersch CL, Wang M, Wen B, Sun D, Carlson K, Katzenellenbogen JA, Xu G, Zhang W, Wu W, Priestley ES, Sui Z, Rae JM, Wang S. J Med Chem, 2024 Dec 12; 67 (23): 20933 - 20965. DOI:10.1021/acs.jmedchem.4c01401
      PMID: 39585895
    • Journal Article
      Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer.
      Pusztai L, Hoag JR, Albain KS, Barlow WE, Stemmer SM, Meisner A, Hortobagyi GN, Shak S, Rae JM, Baehner R, Sharma P, Kalinsky KM. J Clin Oncol, 2024 Dec 2; JCO2401507 DOI:10.1200/JCO-24-01507
      PMID: 39621968
    • Journal Article
      Discovery of ERD-1233 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader for the Treatment of ER+ Human Breast Cancer.
      Acharyya RK, Rej RK, Hu B, Chen Z, Wu D, Lu J, Metwally H, McEachern D, Wang Y, Jiang W, Bai L, Tošović J, Gersch CL, Xu G, Zhang W, Wu W, Priestley ES, Sui Z, Sarkari F, Wen B, Sun D, Rae JM, Wang S. J Med Chem, 2024 Nov 14; 67 (21): 19010 - 19037. DOI:10.1021/acs.jmedchem.4c01521
      PMID: 39485242
    • Journal Article
      Nonlinear Mixed-Effects Model of Z-Endoxifen Concentrations in Tamoxifen-Treated Patients from the CEPAM Cohort.
      Mc Laughlin AM, Helland T, Klima F, Koolen SLW, van Schaik RHN, Mathijssen RHJ, Neven P, Swen JJ, Guchelaar H-J, Dalenc F, White-Koning M, Michelet R, Mikus G, Schroth W, Mürdter T, Brauch H, Schwab M, Søiland H, Mellgren G, Thomas F, Kloft C, Hertz DL, CYP2D6 Endoxifen Percentage Activity Model (CEPAM) Consortium . Clin Pharmacol Ther, 2024 Sep; 116 (3): 690 - 702. DOI:10.1002/cpt.3238
      PMID: 38494911
    • Journal Article
      Artificial intelligence to unlock real-world evidence in clinical oncology: A primer on recent advances.
      Bryant AK, Zamora-Resendiz R, Dai X, Morrow D, Lin Y, Jungles KM, Rae JM, Tate A, Pearson AN, Jiang R, Fritsche L, Lawrence TS, Zou W, Schipper M, Ramnath N, Yoo S, Crivelli S, Green MD. Cancer Med, 2024 Jun; 13 (12): e7253 DOI:10.1002/cam4.7253
      PMID: 38899720
    • Journal Article
      Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms.
      Liang Y, Gersch CL, Lehman J, Henry NL, Smith KL, Rae JM, Stearns V, Hertz DL. Pharmacogenet Genomics, 2024 Jun 1; 34 (4): 126 - 129. DOI:10.1097/FPC.0000000000000522
      PMID: 38359166
    • Proceeding / Abstract / Poster
      Development and validation of RSClin N+ tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer.
      Pusztai L, Hoag JR, Albain KS, Barlow WE, Stemmer SM, Meisner A, Hortobagyi GN, Shak S, Hayes DF, Rae JM, Baehner F, Sharma P, Kalinsky K. Journal of Clinical Oncology, 2024 Jun 1; 42 (16_suppl): 508 - 508. DOI:10.1200/jco.2024.42.16_suppl.508
    • Journal Article
      Incorporation of emergent symptoms and genetic covariates improves prediction of aromatase inhibitor therapy discontinuation.
      Rattsev I, Stearns V, Blackford AL, Hertz DL, Smith KL, Rae JM, Taylor CO. JAMIA Open, 2024 Apr; 7 (1): ooae006 DOI:10.1093/jamiaopen/ooae006
      PMID: 38250582